Business Context and Reporting Period
This Form 8-K Current Report was filed by Athira Pharma, Inc. (not Leonabio, Inc.) on June 16, 2021. The filing addresses significant corporate governance changes involving the departure of the Chief Executive Officer and the appointment of an interim successor.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on executive personnel changes and compensation arrangements.
Material Changes
- CEO Departure: Leen Kawas, Ph.D., President and CEO, was placed on temporary paid leave pending a review of actions stemming from doctoral research conducted at Washington State University. Dr. Kawas remains a Board member.
- Interim Leadership: Mark Litton, Ph.D., MBA, Chief Operating Officer, assumed day-to-day responsibilities as President and CEO effective immediately.
- Investigation: An independent special committee was formed to review the matter regarding Dr. Kawas.
Guidance, Outlook, and Compensation Details
The filing contains no financial guidance or operational outlook. It details the compensation structure for the interim CEO, Dr. Litton:
- Base Salary: $430,000 annually.
- Target Bonus: 40% of annual base salary for 2021.
- Severance (Standard Termination): 9 months' base salary, 9 months' COBRA coverage, and 25% acceleration of 2019 option awards.
- Severance (Change in Control): 12 months' base salary, 100% target bonus, 12 months' COBRA coverage, and 100% acceleration of service-based equity awards.
Investor Verification Checklist
- Verify the status and findings of the independent special committee's review of Dr. Kawas's doctoral research.
- Confirm whether Dr. Litton's interim role will transition to a permanent CEO appointment.
- Review the Company's recent Form S-1/A (filed September 9, 2021) for full details on the Executive Incentive Compensation Plan and Change in Control agreements referenced in this filing.
- Monitor for any future disclosures regarding the resolution of the investigation and potential impact on the Company's leadership stability.